AB Science (OTCMKTS:ABSCF – Get Free Report) is expected to be posting its results after the market closes on Friday, September 25th. Analysts expect AB Science to post earnings of ($0.0799) per share and revenue of $0.6850 million for the quarter.
AB Science Price Performance
OTCMKTS ABSCF opened at $1.12 on Wednesday. AB Science has a 52-week low of $1.12 and a 52-week high of $1.37. The firm has a 50-day moving average price of $1.12 and a 200 day moving average price of $1.21.
AB Science Company Profile
AB Science is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the discovery and development of protein kinase inhibitors. Its core focus is on the design of orally administered small-molecule therapies that target key signaling pathways involved in oncology, inflammatory disorders and neurodegenerative diseases. The company’s lead asset, masitinib, is a selective tyrosine kinase inhibitor that has been evaluated in multiple Phase 2 and Phase 3 clinical trials, including studies in mastocytosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and severe asthma.
Since its founding in 2001 by Dr.
Featured Articles
- Five stocks we like better than AB Science
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for AB Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Science and related companies with MarketBeat.com's FREE daily email newsletter.
